HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Effect of zatebradine, a specific bradycardic agent, on ischemia-induced arrhythmias in anesthetized rabbits.

Abstract
The effects of the specific bradycardic agent, zatebradine (UL-FS 49), on ventricular arrhythmias occurring during an acute ischemia were compared to those of verapamil. Anesthetized rabbits were submitted to a ligation of the left circumflex coronary artery for 20 min. Zatebradine (150 and 750 micrograms/kg, i.v.) dose-dependently reduced heart rate, but changed neither the left ventricular pressure nor the (+)dp/dtmax. In comparison, verapamil (150 and 750 micrograms/kg, i.v.) reduced heart rate, systemic blood pressure, left ventricular pressure and (+)dp/dtmax. The incidence of ventricular premature beats occurring during acute ischemia was changed neither by zatebradine nor by verapamil. Ventricular fibrillation, occurring in 36% of the saline-treated rabbits, was reduced to 18% in the presence of 750 micrograms/kg of zatebradine and 0% with verapamil (750 micrograms/kg, p < 0.05). The action of zatebradine on ischemia-induced ventricular fibrillation, albeit limited, was completely reversed by atrial pacing to the predrug heart rate. To further investigate the mechanisms involved in the antiarrhythmic potential of both zatebradine and verapamil, their electrophysiological actions were compared in canine Purkinje fibers. Both zatebradine and verapamil induced a dose-dependent increase in action potential duration (APD) measured at 90% repolarization. The APDs measured during the plateau level (APD30) and at 50% of the repolarization (APD50) were shortened by verapamil and increased by zatebradine showing that at the concentrations used, zatebradine did not exhibit any calcium antagonistic activity when compared to verapamil. The results of the present study suggest that the specific bradycardic agent zatebradine showed a beneficial action mainly because of its anti-ischemic properties. However, the present studies performed in anesthetized rabbits suggest that in this species pure reduction in heart rate is not sufficient to entirely prevent ischemic arrhythmias.
AuthorsA Bril, M C Forest, B Cheval, L Landais, B Gout
JournalPharmacology (Pharmacology) Vol. 48 Issue 5 Pg. 308-19 (May 1994) ISSN: 0031-7012 [Print] Switzerland
PMID8016191 (Publication Type: Comparative Study, Journal Article)
Chemical References
  • Benzazepines
  • Cardiovascular Agents
  • Verapamil
  • zatebradine
Topics
  • Action Potentials (physiology)
  • Animals
  • Arrhythmias, Cardiac (drug therapy, etiology)
  • Benzazepines (pharmacology, therapeutic use)
  • Cardiovascular Agents (pharmacology, therapeutic use)
  • Dogs
  • Dose-Response Relationship, Drug
  • Electrophysiology
  • Female
  • Heart Ventricles
  • Hemodynamics (drug effects, physiology)
  • Injections, Intravenous
  • Male
  • Myocardial Ischemia (complications)
  • Purkinje Fibers (drug effects, physiology)
  • Rabbits
  • Verapamil (pharmacology)

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: